AVITA Medical's RECELL Technology Reduces Hospital Stays for Burn Patients.

AVITA Medical highlighted data from the British Burn Association Annual Meeting showing that patients treated with RECELL had a reduced hospital stay. The analysis, representing the largest real-world study of skin cell suspension autograft, found that RECELL required less donor skin and offered benefits such as less pain, faster healing, and improved outcomes compared to traditional skin grafting. The patented RECELL technology uses a patient's own skin to produce Spray-On Skin Cells, an autologous cell suspension that supports wound healing.

Valencia, Calif., June 09, 2025 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) has highlighted data presented at the British Burn Association (BBA) Annual Meeting, demonstrating significant reductions in hospital stay among burn patients treated with RECELL®. The session, titled "The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective," represents the largest real-world analysis of skin cell suspension autograft to date. The patented RECELL technology uses a small sample of a patient’s own skin to produce Spray-On Skin™ Cells, an autologous cell suspension that supports wound healing throughout the wound bed.

The retrospective study, presented by Jeffrey E. Carter, MD, FACS, FABA, of Louisiana State University Health and Sciences Center and University Medical Center in New Orleans, analyzed registry data from over 6,300 patients treated with RECELL between 2019 and 2024. Key findings from patients with burns covering less than 30% total body surface area (TBSA) include a significant reduction in length of stay for patients treated with RECELL Spray-On Skin Cells alone by 6.2 days or 35.7% compared to those with split-thickness autografts. This resulted in cost savings of approximately $300 million over the 5-year study period, driven by reduced length of stay.

"Reducing hospital length of stay has a direct impact on the cost of care, especially in complex cases like severe burns," said Jim Corbett, Chief Executive Officer of AVITA Medical. "This analysis further supports previously published data, reaffirming RECELL’s proven clinical and economic value by reducing hospital stays and accelerating patient recovery."

The study underscores the clinical benefits of RECELL, which include less pain at the donor site, faster healing, improved outcomes, and fewer procedures. These advantages contribute to shorter hospital stays and associated cost savings. "From a national registry perspective, we are seeing significant hospital savings and a clearer understanding of how newer technologies like RECELL impact clinical decisions, length of stay, and patient outcomes," said Dr. Carter.

RECELL is used in more than 130 burn centers across the United States, highlighting its widespread adoption and effectiveness in burn care. The technology complements AVITA Medical’s existing product portfolio, which includes the Cohealyx™ collagen-based dermal matrix and the PermeaDerm® biosynthetic wound matrix.

References:
[1] https://finance.yahoo.com/news/avita-medical-highlights-largest-real-130000514.html
[2] https://www.stocktitan.net/news/RCEL/avita-medical-announces-first-clinical-publication-dajp0mva47ii.html
[3] https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1580994/full